Chronic inflammatory demyelinating polyradiculoneuropathy
Drug research and approvals for chronic inflammatory demyelinating polyradiculoneuropathy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 37 studies of chronic inflammatory demyelinating polyradiculoneuropathy are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 37
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Multimodal Characterization of Movement Trajectories in Chronic Inflammatory Demyelinating PolyneuropathyNCT07882797 · Not reported · Heinrich-Heine University, Duesseldorf · starts Oct 23, 2026
- A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic…NCT07540221 · Phase 3 · Grifols Therapeutics LLC · starts Apr 2, 2026
- Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory…NCT07526493 · Phase 1 · Tongji Hospital · starts Apr 1, 2026
- Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDPNCT07461896 · Not reported · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · starts Mar 3, 2025
- CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune DiseasesNCT07337785 · Early Phase 1 · Tongji Hospital · starts Dec 12, 2025
- Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual TreatmentNCT07304154 · Phase 1 · Kite, A Gilead Company · starts Apr 10, 2026
- Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart DevicesNCT07273903 · Not reported · Heinrich-Heine University, Duesseldorf · starts Jan 15, 2026
- Real-World Efgartigimod Effectiveness in CIDP: A Prospective StudyNCT07264426 · Not reported · argenx · starts Aug 11, 2025
- Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)NCT07154524 · Not reported · University of Ulm · starts Aug 27, 2025
Phase 3 6
- Human immunoglobulin gReplacement therapy, immunomodulatory effects
- RituximabB-lymphocyte antigen CD20 binding agent
- FingolimodSphingosine 1-phosphate receptor agonist
- Albumin humanBilirubin sequestering agent
- Hyaluronidase (human recombinant)Hyaluronic acid hydrolytic enzyme
- Riliprubart
Phase 2 10
- RozanolixizumabIgG receptor FcRn large subunit p51 inhibitor
- Efgartigimod alfaIgG receptor FcRn large subunit p51 antagonist
- CytarabineDNA inhibitor
- PrednisoneGlucocorticoid receptor agonist
- CarmustineGlutathione reductase inhibitor
- Interferon beta-1aInterferon alpha/beta receptor agonist
- CyclophosphamideDNA inhibitor
- NipocalimabIgG receptor FcRn large subunit p51 antagonist
- BatoclimabIgG receptor FcRn large subunit p51 inhibitor
- Lipoic acid, alpha
How its trials ended
98 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 25 whose ending is known, 32% met their primary endpoint, 20% missed it and 48% stopped early.
- Ongoing3435%
- Completed, result not reported3132%
- Met its primary endpoint88%
- Stopped: other or unclear88%
- Status unknown88%
- Missed its primary endpoint55%
- Stopped: sponsor or business decision33%
- Stopped: enrollment or feasibility11%
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Feb 14, 2018 | Recombinant humanized IgG4 monoclonal antibody against…Treatment of chronic inflammatory demyelinating polyradiculoneuropathy/polyneuropathy (CIDP) | GeNeuro S.A. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA